(Reuters) - A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/Usx9dVFeiaw/story01.htm
Read More
No comments:
Post a Comment